Description:
<p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Aim: Pancreatic ductal adenocarcinoma (PDAC) has high mortality and early stage metastatic potential.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Thus, the developing new clinical approach and metastasis blocking strategy-based drugs are</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">essential for cure of PDAC. In this study we aimed to investigate the effects of cell surface transmembrane</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">glycoprotein CD44 on the regulation of key ECM proteins, integrin β1, fibronectin and</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">collagen IV, in Panc-1 and MiaPaCa-2 cells.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Materials and Methods: Followed by cell viability assay using MTS, fibronectin and collagen IV</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">protein expression levels and integrin β1 mRNA level were analyzed in Panc-1 and MiaPaCa-2 cells</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">treated with 50 nM negative siRNA and CD44 siRNA for 72 h using western blot and RT-PCR, respectively.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Results: Based on our findings, the downregulation of CD44 using specific siRNA led to decrease</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">fibronectin and collagen IV proteins expressions, and also Integrin β1 mRNA expression in both</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Panc-1 and MiaPaCa-2 cell lines.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Conclusion: CD44 siRNA based therapies have effective role to inhibit ECM degradation in PDAC</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">progression. CD44 is also promising target for against PDAC through inhibiting migration, invasion</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">and metastasis steps.</p>